CSIMarket
 
Immunic Inc   (IMUX)
Other Ticker:  
 
 
Price: $1.4650 $0.07 4.643%
Day's High: $1.47 Week Perf: 20.08 %
Day's Low: $ 1.36 30 Day Perf: 21.07 %
Volume (M): 658 52 Wk High: $ 3.11
Volume (M$): $ 964 52 Wk Avg: $1.56
Open: $1.41 52 Wk Low: $0.95



 Market Capitalization (Millions $) 65
 Shares Outstanding (Millions) 44
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -94
 Cash Flow (TTM) (Millions $) -60
 Capital Exp. (TTM) (Millions $) 0

Immunic Inc
Immunic Inc is a biopharmaceutical company that focuses on developing and commercializing therapies for chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug development technology platform to discover potential drug candidates. They are primarily engaged in the development of oral small molecule drugs for treating immune-related diseases including multiple sclerosis, inflammatory bowel disease, and psoriasis. Immunic Inc aims to improve the lives of patients suffering from these diseases by offering effective and convenient treatment options.


   Company Address: 1200 Avenue of the Americas, New York, 10036 NY
   Company Phone Number: 255-9818   Stock Exchange / Ticker: NASDAQ IMUX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Immunic Inc

IMUX Reveals Impressive Financial Progress in Fourth Quarter of 2023

In the ongoing earnings cycle for the fiscal period of October to December 31, 2023, several companies in the Major Pharmaceutical Preparations sector have reported their financial results. One of these companies, IMUX, recently disclosed an operating deficit of $-23.381 million for the fiscal interval ending December 31, 2023. This represents a significant improvement compared to the operating deficit of $-57.327 million reported in the fourth quarter of 2022.
The reduction in operating deficit shows positive signs for IMUX as the company continues to refine its business model and strive for financial sustainability. Additionally, there has been a notable decrease in net loss, with losses decreasing from $-56.474 million in the fourth quarter of 2022 to $-21.572 million in the most recent fiscal period.

Immunic Inc

Immunic Inc's Third Quarter Performance Dismays Investors with $-23.57 Million Loss

/>The Major Pharmaceutical Preparations sector is closely analyzing the financial results of Immunic Inc. for the third quarter of 2023. The company, known as IMUX in the market, recently reported an operating loss of $-23.57 million for the July to September quarter. Despite the absence of any mention of top-line figures, investors anticipate the emergence of new revenue sources in the near future. However, the IMUX's recent organizational and operational excellence has not instilled confidence among investors. The third quarter of 2023 earnings season has magnified the challenges faced by the company, with shortfalls reaching $-22.769 million. Immunic Inc is expected to release its next financial report on February 22, 2024. In the meantime, the company's stock has experienced a decline of -10.17% in the past 5 days, resulting in a year-to-date performance of -24.29%. Despite this setback, Immunic Inc stock is still trading 8.2% above its 52-week low.
Body:
The recent financial results of Immunic Inc., a major player in the Major Pharmaceutical Preparations sector, have raised concerns among investors. The company, known as IMUX in the market, reported an operating loss of $-23.57 million for the third quarter of 2023. Notably, there was no mention of any top-line figures, leaving analysts and investors speculating about the company's revenue sources.

Immunic Inc

Immunic Inc Experiences Escalation in Operational Expenditure Amid Second Quarter of 2023, Mirroring Trends in Major Pharmaceutical Preparations Industry

Immunic Inc: A Promising Future in Pharmaceutical Preparations
In the ever-evolving realm of pharmaceutical preparations, Immunic Inc has emerged as a strong contender, demonstrating resilience and determination in the face of challenges. Despite recent negative financial figures, the company's stock has shown remarkable growth. With the markets eagerly anticipating new revenue sources, Immunic Inc is well-positioned to capitalize on the bullish sentiments surrounding the Major Pharmaceutical Preparations industry.
The second quarter of 2023 proved to be a testing period for Immunic Inc, as the company reported a net loss of $-23.999 million. While this may raise concerns for some investors, it is essential to remember that successful companies often experience intermittent setbacks while navigating the path to profitability. These occasional hiccups are normal, especially for firms proactively seeking lucrative revenue streams.

Immunic Inc

Struggling Immunic Inc Reveals Challenging First Quarter Results, Casting Doubt on Future Returns

Investors and stakeholders in the stock market must approach Immunic Inc with caution due to its recording of a cumulative net loss of $-125 million in the 12 months ending in the first quarter of 2023, resulting in a negative ROI of -113.12%. With 575 other companies in the healthcare sector recording higher ROIs, Immunic Inc's poor performance is apparent. While the company's overall ROI ranking has progressed from 4595 in the fourth quarter of 2022 to 3095 in the Mar 31, 2023 quarter, this should not be relied upon as the entity is still struggling to generate positive returns.
According to the company's first-quarter earnings report, Immunic Inc booked an operating loss of $-27.251 million, adding to its negative net loss of $-25.272 million, which has widened significantly from $-20.808 million in the first quarter of 2022. This lack of revenue and poor financial performance raises concerns among investors about the company's business model, strategy and its ability to generate positive returns in the futureMoreover, Immunic Inc's development stage suggests that stakeholders should expect the arrival of further business models as soon as feasible, while the company's current expertise may not be sufficient to support its growth. Therefore, it is essential for investors and stakeholders to perceive Immunic Inc with caution and scrutinize their investment decisions as they await the company's next financial results report, which is set to be released on August 03, 2023.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com